Literature DB >> 19530951

Long-term results of percutaneous nephrolithotomy: does prophylactic medical stone management make a difference?

Dorit E Zilberman1, Glenn M Preminger.   

Abstract

It has been almost 30 years since the introduction of percutaneous nephrolithotomy (PCNL) as a safe, effective, and efficient method for large stone fragmentation and removal. While considered a highly effective technique, a surgical procedure alone cannot address the underlying metabolic conditions that may cause either new stone formation or regrowth of residual stones. Reviewing the English literature reveals a relative paucity of controlled studies that explore the long-term effects of metabolic evaluation and medical management on stone recurrence rates. Yet, when retrospectively analyzing the present data, one can see that metabolic and environmental factors are of paramount significance. Medical stone prophylaxis should not be overlooked, because the proper establishment of medical therapy after PCNL may result in stabilization of stone disease and prevention of the need for further surgical procedures for stone removal.

Entities:  

Mesh:

Year:  2009        PMID: 19530951     DOI: 10.1089/end.2009.0118

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  3 in total

Review 1.  Aspects on how extracorporeal shockwave lithotripsy should be carried out in order to be maximally effective.

Authors:  Hans-Göran Tiselius; Christian G Chaussy
Journal:  Urol Res       Date:  2012-06-27

Review 2.  Recent finding and new technologies in nephrolitiasis: a review of the recent literature.

Authors:  Marco Rosa; Paolo Usai; Roberto Miano; Fernando J Kim; Enrico Finazzi Agrò; Pierluigi Bove; Salvatore Micali
Journal:  BMC Urol       Date:  2013-02-16       Impact factor: 2.264

3.  A prospective study assessing feasibility of performing percutaneous nephrolithotomy in chronic kidney disease patients - What factors affect the outcome?

Authors:  Rohan Patel; Samarth Agarwal; S N Sankhwar; Apul Goel; B P Singh; Manoj Kumar
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.